Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay. 1977

N R Bachur, and C E Riggs, and M R Green, and J J Langone, and H Van Vunakis, and L Levine

In 38 adriamycin experiments and 4 daunorubicin experiments, radioimmunoassay readily and reproducibly detects and estimates these drugs and immunologically similar metabolites in patients' plasma and urine to at least 120 hr after dosing without interference by concurrent medication. The plasma drug decay follows first-order kinetics in a triphasic pattern. Radioimmunoassay and fluorescence assay show similar decay up to 4 hr but diverge at that point with the fluorescence assay yielding higher values. Pharmocokinetic differences are amplified in patients with liver dysfunction and may be caused by fluorescent drug metabolites not sensitive to radioimmunoassay or nonspecific fluorescent materials. The radioimmunoassay offers the capability to measure adriamycin and daunorubicin in clinical settings in which fluorescence assay is not available.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008722 Methods A series of steps taken in order to conduct research. Techniques,Methodological Studies,Methodological Study,Procedures,Studies, Methodological,Study, Methodological,Method,Procedure,Technique
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005470 Fluorometry An analytical method for detecting and measuring FLUORESCENCE in compounds or targets such as cells, proteins, or nucleotides, or targets previously labeled with FLUORESCENCE AGENTS. Fluorimetry,Fluorometric Analysis,Analysis, Fluorometric
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

N R Bachur, and C E Riggs, and M R Green, and J J Langone, and H Van Vunakis, and L Levine
January 1981, Acta pharmaceutica Suecica,
N R Bachur, and C E Riggs, and M R Green, and J J Langone, and H Van Vunakis, and L Levine
November 1982, Horumon to rinsho. Clinical endocrinology,
N R Bachur, and C E Riggs, and M R Green, and J J Langone, and H Van Vunakis, and L Levine
July 1970, British heart journal,
N R Bachur, and C E Riggs, and M R Green, and J J Langone, and H Van Vunakis, and L Levine
September 1981, Cancer research,
N R Bachur, and C E Riggs, and M R Green, and J J Langone, and H Van Vunakis, and L Levine
September 1974, Cancer research,
N R Bachur, and C E Riggs, and M R Green, and J J Langone, and H Van Vunakis, and L Levine
April 1984, Journal of pharmaceutical sciences,
N R Bachur, and C E Riggs, and M R Green, and J J Langone, and H Van Vunakis, and L Levine
March 1978, Cancer research,
N R Bachur, and C E Riggs, and M R Green, and J J Langone, and H Van Vunakis, and L Levine
November 1974, The Journal of pharmacology and experimental therapeutics,
N R Bachur, and C E Riggs, and M R Green, and J J Langone, and H Van Vunakis, and L Levine
July 1975, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
N R Bachur, and C E Riggs, and M R Green, and J J Langone, and H Van Vunakis, and L Levine
January 1973, Acta endocrinologica. Supplementum,
Copied contents to your clipboard!